Table 3. The cumulative incidences of post-transplant complications according to donor-type groups

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Complications | MSD | WM-URD | PM-URD | *P* |
| Cumulative incidence at 6 yrs (95% CI) | | |
| Infectious complication (grade ≥ 3)1 | 26.1% (19.3–33.5) | 35.2% (24.2–46.4) | 57.6% (38.6–72.6) | < 0.01 |
| CMV reactivation requiring preemptive therapy | 43.8% (35.8–51.5) | 36.1% (25.1–47.2) | 51.5% (33.1–67.2) | 0.21 |
| CMV disease | 4.6% (2.0–8.7) | 8.3% (3.4–16.2) | 6.2% (1.1–18.2) | 0.53 |
| Herpes zoster | 30.8% (23.4–38.4) | 28.4% (18.3–39.4) | 45.5% (27.7–61.6) | 0.12 |
| Hemorrhagic cystitis (grade ≥ 2) | 7.3% (3.8–12.1) | 6.9% (2.5–14.4) | 15.2% (5.4–29.5) | 0.31 |
| Sinusoidal obstruction syndrome | 0.7% (0.1–3.3) | 4.2% (1.1–10.7) | 0% | 0.11 |

1 indicates *P* = 0.04 between the MSD and the WM-URD groups and *P* < 0.01 between the MSD and the PM-URD groups.

*CI* confidence interval, *MSD* matched sibling donor, *WM-URD* well-matched unrelated donor, *PM-URD* partially matched unrelated donor, *CMV* cytomegalovirus